Articles tagged "Rejection"

2022 American Transplant Congress
Circulating and Intragraft Donor (HLA)-Specific B Cells Drive Allograft Rejection After Kidney Transplantation
A. Torija¹, N. Bolaños¹, L. Donadeu¹, M. Meneghini², I. Torres², A. Gabaldon², M. Gomà³, E. Crespo¹, F. Moreso⁴, O. Bestard²
¹Vall d'Hebron Research Institute (VHIR), Barcelona, Spain, ²Vall d'Hebron University Hospital, Barcelona, Spain, ³Bellvitge University Hospital, Barcelona, Spain, ⁴Vall d'Heron University Hospital, Barcelona, Spain
*Purpose: Besides donor-specific antibodies (DSA), circulating donor(HLA)-specific memory B cells (mBc) have also shown to play a deleterious role driving antibody-mediated rejection (ABMR) in kidney…
2022 American Transplant Congress
Urinary Cell mRNA Profile Diagnosis of Borderline TCMR in Kidney Allografts
T. Salinas¹, C. Li¹, C. Snopkowski¹, K. Chen¹, S. Albakry¹, S. P. Salvatore², S. Seshan², J. R. Lee¹, M. Thangamani¹, D. Dadhania¹, M. Suthanthiran¹
¹Nephrology, Weill Cornell-NYPH, New York, NY, ²Pathology, Weill Cornell-NYPH, New York, NY
*Purpose: Borderline T cell-mediated rejection (BR) is associated with inferior outcomes. In the multicenter CTOT-04 study, we discovered and validated a urinary cell three-gene signature…
2022 American Transplant Congress
Synergistic Effect of CXCR5⁺CD8⁺ T_Ab-supp Cell Adoptive Cell Therapy and mTOR Inhibition (but Not Calcineurin Inhibition) in Suppressing Alloantibody Following Kidney Transplant in Mice
J. L. Han¹, J. M. Zimmerer¹, Q. Zeng², S. Chaudhari¹, C. K. Breuer², G. L. Bumgardner¹
¹Dept. of Surgery, The Ohio State University, Columbus, OH, ²Center for Regen. Med., The Research Institute at Nationwide Children's Hospital, Columbus, OH
*Purpose: We have reported that CXCR5+CD8+TAb-supp cells mediate suppression of alloantibody (alloAb) production and prolong graft survival in both hepatocellular and kidney transplant (KTx) mouse…
2022 American Transplant Congress
Significance of Gene Polymorphism on Infectious Complications and Rejection After Liver Transplantation
H. Egawa¹, T. Kato¹, Y. Kotera¹, Y. Hirata¹, S. Yamashita¹, S. Ariizumi¹, T. Ishizuka¹, Y. Tanaka², H. Ohdan³
¹Tokyo Women's Medical University, Tokyo, Japan, ²Surgery, Hiroshima University, Hiroshima, Japan, ³Hiroshima University, Hiroshima, Japan
*Purpose: Clinical application of gene polymorphism is a key of precision medicine in the field of organ transplantation. Hiroshima group reported significance of Fc-gamma receptor…
2022 American Transplant Congress
Assessing Proportion of Days Covered (PDC) of Mycophenolate (MCP) Prescriptions in Post Kidney Transplant (KT) Recipients as a Predictor of Clinical Outcomes
K. Sandlin¹, T. Sam¹, N. Wilson¹, A. Yango², B. Fischbach³, A. Dao¹
¹Pharmacy, Baylor University Medical Center, Dallas, TX, ²Baylor All Saints Medical Center, Dallas Nephrology Associates, Fort Worth, TX, ³Baylor University Medical Center, Dallas Nephrology Associates, Dallas, TX
*Purpose: Nonadherence to medications following KT is a risk factor for adverse outcomes. PDC is an objective measure of adherence obtained through retail prescription records…
2022 American Transplant Congress
Impact of Sars-CoV-2 Vaccination on Donor-Derived Cell Free DNA Levels in Renal Transplant Recipients
H. Alvarado Verduzco, E. Daniel, D. Kim, A. Hussain, S. Mohan, D. Cohen
Columbia University Irving Medical Center, New York, NY
*Purpose: COVID-19 poses a disproportionate threat to renal transplant recipients (RTR), who are chronically immunosuppressed. Studies have indicated a 16% mortality rate compared to
2022 American Transplant Congress
Early Experience with OmniGraf® Biomarker Surveillance in Kidney Transplant Patients in the First-Year Post-Transplant and Beyond
V. Paramasivam¹, W. Ally², B. Sivakumar³, B. Greco¹, M. Germain¹
¹Baystate Medical Center, Springfield, MA, ²Eurofins Transplant Genomics, Framingham, MA, ³Dartmouth College, Hanover, NH
*Purpose: Non-invasive rejection biomarkers continue to evolve with recent data supporting the use of combined gene expression and donor derived cell-free DNA (dd-cfDNA) in kidney…
2022 American Transplant Congress
Evaluation of the Significance of Isolated C4d Staining without Histological Evidence of Rejection on Kidney Biopsies After ABO-Compatible Transplantation in Pediatric Recipients
C. Duneton¹, M. Rabant², J. Duong-Van-Huyen², V. Baudouin¹, E. Cheyssac¹, O. Boyer³, J. Hogan¹
¹Pediatric Nephrology, Robert Debré Hospital, APHP, Paris, France, ²Pathology, Necker Hospital, Paris, France, ³Pediatric Nephrology, Necker Hospital, Paris, France
*Purpose: C4d staining in peritubular capillaries has been part of ABMR Banff definition since 2003. Despite relatively high specificity, c4d staining shows limited sensitivity, and…
2022 American Transplant Congress
Outcomes of Hlai Kidney Transplants in Patients with Cpra 100% After Desensitization
A. A. Vo¹, J. Tang¹, S. Williamson¹, C. Meyers¹, E. Huang¹, X. Zhang², M. Haas³, A. Peng¹, R. Najjar¹, S. Supreet¹, N. Ammerman¹, K. Lim¹, M. Gillespie¹, N. Badash¹, S. Jordan¹
¹Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, ²HLA Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA, ³Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: The KAS implementation was aimed at increasing access to kidney transplantation in highly HLA sensitized (HS) patients. However, combining desensitization (DES) + KAS could…
2022 American Transplant Congress
Obinutuzumab in Kidney Transplantation: Effect on B-cell Counts and Crossmatch Tests
M. M. Nasrallah¹, M. Elalfy¹, Y. Elmesseery², I. Amer¹, P. Malvezzi³, L. Rostaing⁴
¹Misr International Hospital, Cairo, Egypt, ²Misr International Hospital, Caire, Egypt, ³CHU Grenoble-Alpes, Grenoble, France, ⁴Service de Néphrologie, CHU Grenoble-Alpes, Grenoble, France
*Purpose: Resistance to the action of rituximab (RTX), has been documented in several diseases. More recently, obinutuzumab (OBZ) has shown promise where RTX has failed…